Health Care

Teladoc insiders surge: Rodrigues Fernando M. adds 15K shares, fueling bullish sentiment and media buzz—find out what this means for investors.

Insightful analysis of Hinge Health’s insider trades shows disciplined liquidity management, AI‑powered growth, and value‑based care positioning for investors.

Moderna CFO James Mock buys 2,475 shares—showing insider confidence in Moderna’s mRNA strategy, biotech trends, and future growth potential.

Insulet Corp insider buys signal confidence amid volatility—examining WEATHERMAN’s recent purchase, market dynamics, and growth prospects for diabetes‑care investors.

How Chemomab’s new board shake‑up and insider sales could drive a strategic pivot and a potential price rebound.

June 1 insider sales at Pulmonx reveal routine tax‑settlement activity, highlighting the company’s thin liquidity, regulatory challenges and growth opportunities in bronchoscopic devices.

Prasad’s 729‑share sale at $275.53 shows routine insider liquidity, not a confidence shift. Cigna’s solid fundamentals and sector resilience still promise medium‑term upside despite short‑term volatility.

IRHYTHM Holdings insiders buy shares under a conservative plan, signalling confidence amid earnings volatility and a potential upside for investors.

Castle Biosciences insider buying: CEO Derek Maetzold’s Rule 10(b)(5)(1) purchase signals confidence, not distress—focus on pipeline progress, reimbursement, and scaling.

Oncolytics insider sale: Yi Qingqing liquidates her 235 ADSs amid growing executive trades and a fast‑track REOLYSIN pipeline—what this means for investor confidence.